By Jon Coupal and John Moorlach | Just as good scientists are drawn to conclusions by solid data, the decision whether to spend another $345 million by California’s state-run stem-cell research project should be based on an objective analysis as to whether it would be cost-effective. A rigorous cost-benefit analysis is not only fiscally prudent, it avoids being drawn into the moral dilemmas posed by stem-cell research, especially with respect to cells from human embryos.
Created in 2004 with the passage of Proposition 71, the California Institute for Regenerative Medicine was authorized to spend $3 billion in bond proceeds. But as is typical with most bonds, the interest payments would double the cost to $6 billion. CIRM has made $2.4 billion in grants and used $255 million for administration and prepaid interest — leaving $345 million remaining to disburse.
Should CIRM distribute the remaining $345 million (which, with interest, would amount to $690 million in repayment costs)? Should this remaining pool of funds be doled out?
To read the entire column, please click here.